Last 47 quarters of trend data · Healthcare · Drug Manufacturers - General
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 49.80 | 37.77 | 27.84 | 36.36 | 30.72 | 30.98 | 67.48 | 39.55 | 207.00 | 69.01 | 78.42 | 60.22 | — | 63.03 | 60.46 | 44.83 | 50.21 | 77.20 | 35.80 | 38.15 | 49.80 |
| — | +21.9% | -58.7% | -8.1% | -85.2% | -55.1% | -14.0% | -34.3% | — | +9.5% | +29.7% | +34.3% | — | -18.3% | +68.9% | +17.5% | +0.8% | +105.8% | +8.1% | +99.8% | +69.6% | |
| P/S Ratio | 16.51 | 11.66 | 10.40 | 12.51 | 9.74 | 11.27 | 14.61 | 12.88 | 17.52 | 18.11 | 20.05 | 14.08 | 13.42 | 13.39 | 11.71 | 11.90 | 10.53 | 11.28 | 8.71 | 8.23 | 8.16 |
| — | +3.5% | -28.8% | -2.9% | -44.4% | -37.8% | -27.1% | -8.5% | +30.6% | +35.2% | +71.2% | +18.3% | +27.5% | +18.7% | +34.4% | +44.6% | +29.0% | +45.5% | +32.3% | +51.7% | +32.3% | |
| P/B Ratio | 38.68 | 31.64 | 26.41 | 36.37 | 28.75 | 38.23 | 46.94 | 48.85 | 55.99 | 60.04 | 54.52 | 48.51 | 45.09 | 39.93 | 28.86 | 32.26 | 28.75 | 33.81 | 28.77 | 28.77 | 27.79 |
| — | -17.2% | -43.7% | -25.6% | -48.6% | -36.3% | -13.9% | +0.7% | +24.2% | +50.4% | +88.9% | +50.4% | +56.9% | +18.1% | +0.3% | +12.1% | +3.5% | +7.8% | +13.9% | +3.8% | -1.9% | |
| P/FCF | 119.96 | 34.55 | 68.51 | 355.90 | 19.91 | 136.67 | — | 239.90 | — | 3228.09 | 978.19 | — | — | — | 98.54 | 84.86 | 46.70 | 197.96 | 41.45 | 37.37 | 47.00 |
| — | -74.7% | — | +48.4% | — | -95.8% | — | — | — | — | +892.7% | — | — | — | +137.7% | +127.1% | -0.6% | +371.5% | +11.5% | -7.9% | +84.8% | |
| EV / EBITDA | 35.56 | 30.22 | 23.03 | 28.01 | 20.28 | 24.26 | 33.18 | 28.95 | 41.34 | 43.68 | 57.94 | 38.35 | 33.38 | 42.64 | 41.08 | 35.02 | 31.82 | 36.65 | 23.09 | 23.70 | 23.30 |
| — | +24.6% | -30.6% | -3.2% | -50.9% | -44.5% | -42.7% | -24.5% | +23.8% | +2.4% | +41.0% | +9.5% | +4.9% | +16.3% | +77.9% | +47.8% | +36.5% | +24.4% | +0.9% | +49.6% | +11.5% | |
| EV / EBIT | 37.43 | 30.22 | 23.48 | 30.37 | 24.23 | 26.26 | 52.65 | 34.56 | 116.43 | 57.04 | 66.91 | 51.88 | 239.08 | 52.20 | 52.27 | 41.48 | 46.37 | 65.47 | 33.47 | 35.98 | 44.08 |
| — | +15.1% | -55.4% | -12.1% | -79.2% | -54.0% | -21.3% | -33.4% | -51.3% | +9.3% | +28.0% | +25.1% | +415.5% | -20.3% | +56.2% | +15.3% | +5.2% | +98.0% | +8.8% | +111.0% | +73.8% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 83.8% | 85.8% | 81.9% | 85.1% | 82.9% | 84.3% | 82.5% | 82.2% | 81.0% | 80.8% | 80.9% | 80.9% | 80.4% | 78.3% | 76.6% | 78.8% | 77.3% | 78.0% | 73.5% | 74.4% | 78.9% |
| — | +1.8% | -0.7% | +3.4% | +2.3% | +4.3% | +2.0% | +1.7% | +0.8% | +3.3% | +5.6% | +2.6% | +4.1% | +0.4% | +4.3% | +6.0% | -2.1% | +9.8% | +1.5% | -3.3% | +2.6% | |
| Operating Margin | 45.6% | 39.1% | 44.7% | 45.5% | 47.6% | 45.8% | 42.5% | 42.8% | 39.8% | 39.1% | 31.2% | 34.1% | 37.3% | 28.1% | 24.6% | 30.2% | 29.4% | 26.9% | 34.1% | 30.9% | 31.5% |
| — | -14.7% | +5.2% | +6.2% | +19.8% | +17.2% | +36.2% | +25.5% | +6.7% | +39.0% | +26.6% | +12.9% | +27.0% | +4.6% | -27.7% | -2.1% | -6.7% | +19.5% | +32.4% | -3.7% | +20.9% | |
| Net Margin | 31.7% | 30.9% | 37.4% | 34.4% | 31.7% | 36.4% | 21.7% | 32.6% | 8.5% | 26.3% | 25.6% | 23.4% | -0.6% | 21.2% | 19.3% | 26.5% | 20.9% | 14.7% | 24.4% | 21.6% | 16.4% |
| — | -15.1% | +72.3% | +5.6% | +273.9% | +38.6% | -15.3% | +39.2% | +1503.7% | +23.7% | +32.4% | -11.8% | -102.9% | +44.5% | -20.7% | +23.0% | +27.6% | -28.8% | +22.3% | -24.2% | -22.1% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 101.2% | 21.8% | 25.6% | 26.3% | 26.5% | 33.1% | 18.3% | 30.8% | 6.9% | 22.4% | 18.9% | 19.8% | -0.5% | 15.7% | 12.2% | 18.5% | 15.4% | 10.5% | 20.4% | 20.2% | 15.2% |
| — | -34.1% | +39.8% | -14.6% | +281.1% | +48.0% | -2.9% | +56.2% | +1457.9% | +42.3% | +54.9% | +6.7% | -103.3% | +49.5% | -40.4% | -8.3% | +1.5% | -48.0% | -2.5% | -48.4% | -41.8% | |
| ROA | 21.6% | 5.5% | 6.5% | 5.8% | 5.2% | 5.9% | 3.3% | 5.7% | 1.3% | 4.4% | 3.5% | 3.6% | -0.1% | 3.3% | 2.6% | 4.0% | 3.1% | 2.0% | 4.0% | 3.6% | 2.3% |
| — | -7.9% | +96.7% | +2.1% | +293.1% | +36.2% | -6.4% | +59.1% | +1392.5% | +33.8% | +33.8% | -10.1% | -103.3% | +61.1% | -34.1% | +12.3% | +32.8% | -31.0% | +37.1% | -23.8% | -17.8% | |
| ROIC | 41.8% | 9.0% | 10.1% | 11.1% | 11.3% | 10.1% | 8.5% | 10.0% | 8.4% | 8.7% | 5.9% | 7.7% | 9.4% | 6.5% | 5.0% | 6.8% | 6.6% | 5.6% | 8.7% | 8.5% | 7.8% |
| — | -10.4% | +19.5% | +10.8% | +34.6% | +15.4% | +44.1% | +30.6% | -11.0% | +34.1% | +17.7% | +12.2% | +42.7% | +15.3% | -42.9% | -19.7% | -14.9% | -0.1% | +29.8% | -11.6% | +26.6% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.60 | 1.62 | 1.39 | 1.60 | 1.78 | 2.17 | 2.43 | 2.36 | 2.17 | 2.12 | 2.03 | 2.32 | 1.78 | 1.69 | 1.67 | 1.51 | 1.56 | 1.94 | 1.74 | 1.84 | 2.15 |
| — | -25.5% | -42.8% | -32.1% | -18.0% | +2.6% | +19.6% | +1.5% | +21.8% | +25.5% | +21.6% | +54.1% | +14.1% | -13.1% | -4.2% | -18.3% | -27.2% | -21.7% | -23.6% | -35.3% | -36.6% | |
| Debt / EBITDA | 1.36 | 5.94 | 4.63 | 4.76 | 4.80 | 5.25 | 6.56 | 5.36 | 6.20 | 5.98 | 8.36 | 7.04 | 5.10 | 6.96 | 9.09 | 6.29 | 6.62 | 8.03 | 5.33 | 5.79 | 6.80 |
| — | +13.2% | -29.4% | -11.1% | -22.6% | -12.2% | -21.5% | -24.0% | +21.6% | -14.1% | -8.1% | +12.0% | -22.9% | -13.4% | +70.7% | +8.6% | -2.6% | -8.3% | -30.9% | -4.0% | -25.6% | |
| Current Ratio | 1.58 | 1.35 | 1.50 | 1.58 | 1.55 | 1.28 | 1.37 | 1.15 | 1.27 | 1.11 | 1.35 | 0.94 | 1.05 | 1.13 | 1.30 | 1.05 | 1.13 | 1.10 | 1.27 | 1.23 | 1.30 |
| — | +6.0% | +9.1% | +36.9% | +21.5% | +14.7% | +1.3% | +22.4% | +21.7% | -1.2% | +4.2% | -10.4% | -7.2% | +2.9% | +2.6% | -14.2% | -13.4% | -4.4% | -10.6% | -12.4% | -4.0% | |
| Quick Ratio | 1.19 | 1.00 | 1.10 | 1.19 | 1.24 | 1.00 | 1.06 | 0.89 | 0.97 | 0.87 | 1.03 | 0.73 | 0.82 | 0.87 | 1.02 | 0.80 | 0.88 | 0.85 | 0.98 | 0.97 | 1.02 |
| — | +0.8% | +3.5% | +34.1% | +28.0% | +13.8% | +3.5% | +21.2% | +18.0% | +0.1% | +1.0% | -8.7% | -6.7% | +3.3% | +4.0% | -17.2% | -13.2% | -5.2% | -11.6% | -10.4% | -4.1% | |
| Interest Coverage | 33.16 | 26.80 | 27.66 | 66.96 | 41.27 | 28.21 | 15.18 | 23.42 | 9.24 | 20.16 | 15.12 | 19.15 | 4.43 | 18.36 | 15.88 | 25.96 | 20.21 | 14.43 | 25.19 | 23.60 | 15.90 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Bull/bear thesis, analyst target revisions, and earnings execution.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying LLY stock.
Eli Lilly and Company's current P/E is 49.8x. The average P/E over the last 4 quarters is 33.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Eli Lilly and Company's current operating margin is 45.6%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Eli Lilly and Company's business trajectory between earnings reports.